Existing users Log In New users Sign up

HER Profiling in Gastric Adenocarcinoma

DISCOVERIES (ISSN 2359-7232), 2018, October-December issue


Raj N, Verma D, Kumar A, Rai P, Rao RN. HER2 Oncogene Amplification and Immunohistochemical Profiling in Gastric Adenocarcinoma. Discoveries 2018, 6(4): e83. DOI: 10.15190/d.2018.6

Submitted: December 4th, 2018; Revised: December 26th, 2018; Accepted: December 27th, 2018; Published: December 31st, 2018;

 GO BACK to 2018, October-December issue


HER2 Oncogene Amplification and Immunohistochemical Profiling in Gastric Adenocarcinoma

Nisha Raj (1), Divya Verma (1), Ashok Kumar (2), Praveer Rai (3), Ram Nawal Rao (1,*)

(1) Department of Pathology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India 

(2) Department of Surgical Gastroenterology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India

(3) Department of Gastroenterology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India

*Corresponding author: Prof. Ram Nawal Rao, MD, Department of Pathology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Rae Bareli Road, P.O. Box-226014, Lucknow, Uttar Pradesh, India; Tel.: 0522-2495259; E-mail: rnawalrao@gmail.com


Background & Objectives: Gastric adenocarcinoma is one of the most common malignant tumors and a major cause of cancer death worldwide, especially in developing countries. Her2/neu gene amplification and protein overexpression in breast cancer is a golden criterion for the targeted therapy with trastuzumab. However, the role of Her2 as a prognostic factor in gastric cancer is still controversial. The purpose of this study was to evaluate the frequency of Her2 oncogene overexpression and concordance between the results for Her2 protein expression and gene amplification.

Materials & Methods: A total of 65 retroprospective cases with gastric adenocarcinoma, including biopsy and resected specimens obtained between July 2015 to December 2017, were analyzed. Her2/neu expression was determined by Immuno-histochemistry (IHC). Equivocal and some selected cases were submitted for FISH to detect Her2/neu gene amplification.

Results: In the present study, out of 65 patients of gastric adenocarcinoma, there were 50 males and 15 females, with mean age of 54.52 years. The majority of tumors were located within the antropyloric region. We found 27 (41.4%) positivity, scored as IHC 3+ and IHC 2+, and 38 (58.3%) negativity, scored as IHC 1+ and IHC 0. We also evidentiated a significant difference between Her2/neu expression with age (p=0.010) and depth of invasion (p=0.020).

Her2/neu gene was amplified only in 13 cases, 4 cases were of Her2/neu (3+) positive, 11 cases (39.3%) Her2/neu (2+) with IHC staining. The concordance rate between the results of IHC and FISH in all 18 cases was 83.3%.

Conclusion: IHC detection can be carried out to guide the treatment when FISH detection cannot be performed. Overexpression of Her 2/neu in gastric adenocarcinoma could potentially be used in selecting the patients who can get benefit from the anti-Her2/neu targeted therapy.

Patients specimens for this study were acquired and used under the IEC number 2017-21-PhD-95.

Access full text of the manuscript here: 


1. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005; 366:1784–1793.

2. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol. 2009; 71:127–164.

3. Yeole BB. Trends in cancer incidence in esophagus, stomach, colon, rectum and liver in males in India. Asian Pac J Cancer Prev 2008; 9:97-100.

4. Satyanarayana L, Asthana S. Life time risk for development of ten major cancers in India and its trends over the years 1982 to 2000. Indian J Med Sci 2008; 62:35-44.

5. Rastogi T, Devesa S, Mangtani P, et al. Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. Int J Epidemiol 2008; 37:147-60.

6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69–90.

7.Theuer CP, de Virgilio C, Keese G, French S, Arnell T, Tolmos J, Klein S, Powers W, Oh T, Stabile BE. Gastric adenocarcinoma in patients 40 years of age or younger. Am J Surg. 1996; 172:473–476; discussion 473-476.

8. Nakamura T, Yao T, Niho Y, Tsuneyoshi M. A clinicopathological study in young patients with gastric carcinoma. J Surg Oncol. 1999; 71:214–219.

9.Yasui W, Sentani K, Sakamoto N, et al. Molecular pathology of gastric cancer: research and practice. Pathol Res Pract. 2011; 207:608–12.

10. Nobili S, Bruno L, Landini I, et al. Genomic and genetic alterations influence the progression of gastric cancer. World J Gastroenterol. 2011; 17:290–9.

11. Sun M, Nie FQ, Wang ZX, et al. Involvement of lncRNA dysregulation in gastric cancer. Histol Histopathol. 2015; 21:11655.

12. Gravalos C, Jimeno A. Her2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523-29.

13. Rajagopal I, Niveditha SR, Sahadev R, Nagappa PK, Rajendra SG. Her2 expression in gastric and Gastro-Esophageal Junction (GEJ) adenocarcinomas. J Clin Diagn Res. 2015;9:EC06-10.

14. He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H, Shen ZY, Liu Q. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol. 2013; 19:2171–2178.

15. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by Her2 status: A European and USA International collaborative analysis. Ann Oncol. 2012; 23:2656–2662.

16. Baykara M, Benekli M, Ekinci O, Irkkan SC, Karaca H, Demirci U, Akinci MB, Unal OU, Dane F, Turkoz FP, et al. Clinical Significance of Her2 Overexpression in Gastric and Gastroesophageal Junction Cancers. J Gastrointest Surg. 2015; 19:1565–1571.

17. Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H, Kobayashi K, Yokoyama Y, Shaker MN, Takiguchi S, et al. Multicenter large-scale study of prognostic impact of Her2 expression in patients with resectable gastric cancer. Gastric Cancer. 2015; 18:691–697.

18. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol. 2000; 18:2201–2209.

19. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W. Her2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol. 2010; 32:57–65.

20. Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, Jang SJ, Park YS. Evaluation of Her2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol. 2011; 18:2833–2840.

21. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, et al. Her2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006; 51:1371–1379.

22. Wang S, Zheng G, Chen L, Xiong B. Effect of Her2/neu over-expression on prognosis in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2011; 12:1417–1423.

23. Abrahão-Machado LF, Jácome AA, Wohnrath DR, dos Santos JS, Carneseca EC, Fregnani JH, Scapulatempo-Neto C. Her2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays. World J Gastroenterol. 2013; 19:6438–6446.

24. Jørgensen JT, Hersom M. Her2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. J Cancer. 2012; 3:137–144.

25. E. U. Cidon, R. G. Centeno, E. G. Lagarto, and J. I. Peral. Her2 Evaluation in a Specific Gastric Cancer Population with the Highest Rate of Mortality in Spain. Journal of Oncology.2011; 2011; Article ID 391564, 6 pages.

26. Y. Yonemura, I. Ninomiya, A. Yamaguchi et al., “Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer,” Cancer Research, 1991; 51(3):1034–1038.

27.T. Ishida, M. Tsujisaki, Y. Hanzawa et al., “Significance of erbB-2 gene product as a target molecule for cancer therapy,” Scandinavian Journal of Immunology, 1994, 39(5):459–466.

28. A. Tokunaga, M. Onda, T. Okuda et al., “Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer,” Cancer, 75(6):1418–1425.

29. Sekaran A, Kandagaddala RS, Darisetty S, Lakhtakia S, Ayyagari S, Rao GV, et al. Her2 expression in gastric cancer in Indian population--an immunohistochemistry and fluorescence in situ hybridization study. Indian J Gastroenterol. 2012; 31:106–10.

30. Patil PS, Mehta SA, Mohandas KM. Over-expression of Her2 in Indian patients with gastric cancer. Indian J Gastroenterol. 2013; 32:350.

31.Kataoka Y, Okabe H, Yoshizawa A, Minamiguchi S, Yoshimura K, Haga H, et al. Her2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer. 2013;16: 84–93.

32. Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 2012; 18:5992–6000.

33. M. Hofmann et al., Assessment of a Her2 scoring system for gastric cancer: results from a validation study, Histopathology 2008; 52(7):797–805.

34. Ruschoff J, Hanna W, Bilous M et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol, 2012; 25: 637–50.

35. Tomonori Y Ano et. al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncology reports15: 2006, 65-71.

36. Michael F. Press et. al. Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence in Situ Hybridization. Arch Pathol Lab Med—Vol 140, 2016:1250-1258.

37. Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J, Sung JJ. Dysregulation of cellular signaling in gastric cancer. Cancer Lett 2010; 295: 144-153.

38. Yamashita K, Sakuramoto S, Watanabe M. Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications. Surg Today 2011; 41: 24-38.

39. Jan Trost Jorgensen. Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects. World J Gastroenterol 2014 April 28; 20(16): 4526-4535.

40. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, ToGA Trial. Trastuzumab Investigators in combination with chemotherapy versus chemotherapy alone for treatment of Her2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open label, randomized controlled trial. Lancet. 2010;376(9742):687-97.

41. Zeeneldin AA, Ramadan H, El Gammal MM, Saber MM, Elgamal D, Sherisher MA. Gastric carcinoma at Tanta Cancer Center: a comparative retrospective clinico-pathological study of the elderly versus the non-elderly. J Egypt Natl Canc Inst. 2014; 26:127-137.

42. Ahmed Abdel Hadi et.al. Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients. Journal of Medical Sciences. 2016 Dec 15; 4(4):535-542.

43. Rüschoff J, Dietel M, Baretton G, et al. Her2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010; 457:299–307.

44. Bartlett JM, Forsyth A. Detection of Her2 gene amplification by fluorescence in situ hybridization in breast cancer. Methods Mol Med. 2006; 120:309–22.

45. Varis A, Zaika A, Puolakkainen P, et al. Coamplified and overexpressed genes at ERBB2 locus in gastric cancer [J]. Int J Cancer, 2004,109:548- 553.

46. Kim MA, Jung EJ, Lee HS, et al. Evaluation of Her2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction [J]. Hum Pathol, 2007,38:1386-1393.

47. Lakshmi V, Valluru VR, Madhavi J, Valluru N. Role of Her 2 Neu in Gastric Carcinoma-3 Year Study in a Medical College Hospital. Ind J Appl Res. 2014;4(11):47–50.

48. Nisha Raj, Divya Verma, Ashok Kumar, et. al. Prognostic significance of membrane associated human epidermal growth factor receptors 2 in gastric adenocarcinomas. WJPR. 2018; 20184-11025. 

49. Sutapa Halder, Debjani Mallick,et.al. Detection and Significance of Human Epidermal Growth Factor Receptor 2 Expression in Gastric Adenocarcinoma. Indian J Med Paediatr Oncol. 2017 Apr-Jun; 38(2): 153–157.

50. Ling Shan, Jianming Ying, Ning Lu. Her2 expression and relevant clinicopathological features in gastric and gastresophageal junction adenocarcinoma in a Chinese population. Diagnostic Pathology. 2013; 8:76, doi 10.11.86/1746-1596-8-76.

51. Tafe LJ, Janjigian YY, Zaidinski M, Hedvat CV, Hameed MR, Tang LH, et al. Human epidermal growth factor receptor 2 testing in gastresophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Archives of pathology & laboratory medicine. 2011;135(11):1460-65.

52. Daniela Lazar, Sorina Taban, I Sporea. Gastric cancer: correlation between clinicopathological factors and survival of patients. Romanian Journal of Morphology and Embryology. 2009;50(2):185–93.

53. Chen XZ, Zhang WH, Yao WQ, Liu JP, Zhou ZG, Chen ZX. Immunohistochemical Her2 expression not associated with clinico pathological characteristics of stage I-III gastric cancer patients. Hepatogastroenterology. 2015;61(134):1817-21.

54. Yan YS, Ying Hu, Jian-Gao Fan, Guo-Quan Tao, Yong-Ming Lu, Xu Cai. Clinicopathological significance of Her2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol. 2011; 17(11): 1501–1506.

55. De Carli DM, Rocha MP, Antunes LC, Fagundes RB. Immunohistochemical expression of Her2 in adenocarcinoma of the stomach. Arq Gastroenterol. 2015; 52:152–5.

56.Yan Song, et al. Correlation of HER2/ neu gene amplification and protein expression with the prognosis of advanced gastric cancer patients. Chinese Journal of Cancer 2009, 09-23.

57. Yano T, Ochiai A, Doi T, et al. Expression of Her2/neu in gastric cancer: comparison between protein expression and gene amplification using a new commercial kit [J]. J Clin Oncol, 2004,22:14S.

58. Uprak et.al. Her2 incidence in gastric cancer, its association with prognosis and clinicopathological parameters. Ulus Cerrahi Derg 2015; 31:2017-13.

59. Chao He, Xue-Yi Bian, Xing-Zhi Ni, Dan-Ping Shen et.al. Correlation of human epidermal growth factor receptor2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol 2013 April 14; 19(14): 2171-2178.

60. Ming Chen et.al. Comparison of Her2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer. Contemp Oncol (Pozn) 2014; 18 (2): 95–99.

News & Events Latest news from Discoveries

  • 2022, April| AWARDS!

    2022 Discoveries Award winning articles!

    - Kinal Bhatt et al. 2021 (Larking Health System, FL, USA); Bhatt K, Agolli A, Patel MH, et al. High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries. 2021;9(1):e126. 
    27 citations in the past 1 year - $1000 prize

    - Hasnain Jan et al. 2020 (Quaid-i-Azam University, Pakistan); Jan H, Faisal S, Khan A, et al. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. Discoveries. 2020;8(2):e108. 
    23 citations in the past 2 years - $400 prize

    Congratulations! Prizes will be received by the awardees in July 2022!

  • 2021, July| 2021, Jul-September

    Due to the high volume of the submitted articles, both Discoveries and Discoveries Reports are experiencing processing and publication delays during the months of July-September 2021. We will get back to the normal processing and publication times starting in October 2021. Note that our editorial and administrativ work is fully funded by our publishing house at this time and we are striving to KEEP THE NO FEE/NO CHARGE strategy in place as long as possible. 

  • 2021, January| AWARDS!

    2022 DISCOVERIES AWARDS! Discoveries will offer $1000 and $400 awards in early 2022, for the most cited (2021 ISI Citations) and visible articles published in 2018-2021.

  • 2020, November| Follow us on Twitter!

    You can now follow the latest Discoveries news and updates on Twitter! (@DiscoveriesNews) 

  • 2020, August| For Authors!

    Due to a high volume of article submissions, our peer-review process takes more than usual. The pre-screening decision is released in 1-2 days, while the peer-review process lasts between 10 and 20 days.  

  • 2020, April | For Authors!

    WE DO NOT TOLERATE ANY MISCONDUCT! Please be aware that we are testing all received articles with specialized software for PLAGIARISM and WE WILL TAKE MEASURES if your article is already published or in consideration for publication by other journals! This may result in serious professional consequences for the authors. The latest striking case is the following article which is already published and was re-submitted here.  

  • 2020, April | For Authors!

    We are happy to let you know that all articles published in Discoveries are now included in PubMedCentral (PMC). New accepted articles will be included in PMC and PubMed within 1-2 weeks after their publication.

  • 2020, January | For Authors!

    Starting in January 2020, Discoveries will also consider articles submitted by Discoveries' Editorial Board members. However, only a small number of such articles (maximum 4 articles/year) will be considered for publication after the peer-review process, and the authors who are also our editors will be clearly disclosed on our website.  

  • 2019, September | Indexed by PMC

    Discoveries is now indexed by PubMedCentral and Pubmed. The agreement with US National Library of Medicine was signed on September 10, 2019. Our next step is ISI Web of Science indexing. NOTE: previously published articles will be included on PubMed in early 2020.

  • 2019, September | PubMed inclusion!

    We are happy to let you know that Discoveries successfuly passed the last step (Technical Review) required for PubMedCentral and PubMed inclusion!

  • 2019, July | PubMed inclusion News!

    We are happy to receive positive comments from PMC/NLM-NIH regarding Discoveries' last step (Technical Review) required for PubMedCentral and PubMed inclusion. We will let you know once whole indexing process is completed. 

  • 2019| Sharing and Distribution!

    All articles published in Discoveries are Open Access articles distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and it is not used for commercial purposes.

  • 2018-2019 | For Authors!

    From now on and for at least 1 year, we will only accept articles from authors that are NOT members of Discoveries' Editorial Board. All articles submitted by our editors will be immediately rejected until further notice (one accepted article was already rejected). 

  • 2018 | PubMed inclusion News!

    Discoveries successfully passed the Scientific Quality Review by NLM-NIH for PubMedCentral and PubMed indexing. This is the first and the most important step towards PubMedCentral and PubMed indexing! The second (last) step is the Technical Review.

  • 2016, April | Faster Peer-Review

    Starting on April 13th 2016, all articles selected for a peer-review will receive the post peer-review decision within ~10 days. The initial pre-screening time will remain the same (48h from the submission of the manuscript). This decision will significantly accelerate the publication, with no effect on the quality of the peer-review process.

  • 2016, February | Manuscript submission

    Discoveries is commited to excellence, quality and high editorial standards. We are receiving an increasing number of manuscripts for which the identity of the authors/corresponding author can't be verified. Please NOTE that ALL these articles were and will be immediately REJECTED. Indicating an institutional email address is the easiest way to overcome this problem! Moreover, we do not accept any pressure on our editorial board to accept a manuscript. This results in a prompt rejection of the article.

    Editorial Policies
  • 2016, January | Main Objective

    After reaching all proposed milestones until now (including being indexed by Google Scholar in 2014), Discoveries' next Aim is PubMed indexing of all its articles (already published and upcoming). There will be no charge for the submission or publication of articles before Discoveries is indexed.

  • 2015, August | Discoveries - on PubMed

    We are happy to announce that our first Discoveries articles were included in PMC and PubMed. More articles (submitted by NIH funded authors) are now processed for being included.

    Discoveries articles now on PubMed
  • 2015, April | Special Issue

    DISCOVERIES published the SPECIAL ISSUE entitled "INFLAMMATION BETWEEN DEFENSE AND DISEASE: Impact on Tissue Repair and Chronic Sickness".

    Special Issue on "Inflammation"
  • 2015 | Ischemia Collection

    DISCOVERIES launched a call for papers for a Collection of Articles with focus on "ISCHEMIA". If you are interested to submit a manuscript, please contact us at info@discoveriesjournals.org

  • 2014, September | Special Issue

    DISCOVERIES just publish the SPECIAL ISSUE entitled "CELL SECRETION & MEMBRANE FUSION" in September 2014. Initially scheduled for publication between October 2014-March 2015, this issue was successfully published earlier than scheduled. 

    Special Issue
  • 2014, April | Indexed by Google Scholar

    All our published articles are now indexed by Google Scholar! First citations to Discoveries articles are included! Search for the article's title (recommended) or the authors:

    Google Scholar Search
  • 2014 | DISCOVERIES

    DOIs (Digital Object Identifiers) are now assigned to all our published manuscripts in Discoveries. DOI uniquely identifies an article and is provided by CrossRef.

  • 2013, July | Manuscript Submission

    Submit your manuscript FREE, FAST and EASY ! (in less than 1 minute)! There are NO fees for the manuscript submission or publishing of the accepted manuscripts.
    read more

  • 2013, July | DISCOVERIES

    We are now ACCEPTING MANUSCRIPTS for publishing in DISCOVERIES. We aim publishing a small number of high impact experimental articles & reviews (around 40/year) to maintain a high impact factor. Domains of interest: all areas related to Medicine, Biology and Chemistry ...

    read more
Member Login
Free Registration Click here to sign up
Copyright © 2013 Applied Systems. All Rights Reserved.